Based on the measurements of operating efficiency obtained from PolyPid's historical financial statements, PolyPid is not in a good financial situation at this time. It has a very high odds of going through financial crisis in March. At present, PolyPid's Total Stockholder Equity is projected to increase significantly based on the last few years of reporting. The current year's Cash is expected to grow to about 18.9 M, whereas Other Current Liabilities is forecasted to decline to about 1.8 M.
Cash Flow Balance Sheet Income Statement
Covid
Interest Hikes
PolyPid Balance Sheet Chart
At present, PolyPid's Total Stockholder Equity is projected to increase significantly based on the last few years of reporting. The current year's Cash is expected to grow to about 18.9 M, whereas Other Current Liabilities is forecasted to decline to about 1.8 M.
The essential information of the day-to-day investment outlook for PolyPid includes many different criteria found on its balance sheet. An individual investor should monitor PolyPid's cash flow, debt, and profitability to accurately make informed decisions on whether to invest in PolyPid.
Please note, the presentation of PolyPid's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, PolyPid's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of PolyPid's management manipulating its earnings.
PolyPid Stock Summary
PolyPid competes with Annovis Bio, Reviva Pharmaceuticals, Bioatla, Evaxion Biotech, and Celularity. PolyPid Ltd., a late-stage biopharma company, develops, manufactures, and commercializes products based on polymer-lipid encapsulation matrix platform to address unmet medical needs. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel. Polypid operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 75 people.
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
Comparative valuation techniques use various fundamental indicators to help in determining PolyPid's current stock value. Our valuation model uses many indicators to compare PolyPid value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across PolyPid competition to find correlations between indicators driving PolyPid's intrinsic value. More Info.
PolyPid is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . At present, PolyPid's Return On Equity is projected to drop based on the last few years of reporting. Comparative valuation analysis is a catch-all technique that is used if you cannot value PolyPid by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.
Most indicators from PolyPid's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into PolyPid current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in PolyPid. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.
For information on how to trade PolyPid Stock refer to our How to Trade PolyPid Stock guide.At present, PolyPid's Tax Provision is projected to increase significantly based on the last few years of reporting. The current year's Enterprise Value is expected to grow to about 20.4 M, whereas Enterprise Value Over EBITDA is forecasted to decline to (0.43).
Today, most investors in PolyPid Stock are looking for potential investment opportunities by analyzing not only static indicators but also various PolyPid's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of PolyPid growth as a starting point in their analysis.
Price Earnings To Growth Ratio
0.007448
At present, PolyPid's Price Earnings To Growth Ratio is projected to increase slightly based on the last few years of reporting.
PolyPid January 30, 2026 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of PolyPid help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of PolyPid. We use our internally-developed statistical techniques to arrive at the intrinsic value of PolyPid based on widely used predictive technical indicators. In general, we focus on analyzing PolyPid Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build PolyPid's daily price indicators and compare them against related drivers.
When running PolyPid's price analysis, check to measure PolyPid's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy PolyPid is operating at the current time. Most of PolyPid's value examination focuses on studying past and present price action to predict the probability of PolyPid's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move PolyPid's price. Additionally, you may evaluate how the addition of PolyPid to your portfolios can decrease your overall portfolio volatility.